Post-earnings recap
Reported
Thu, Feb 12, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which contributed to a slight increase in stock price. The positive EPS surprise indicates better cost management or operational efficiency. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | +57.58% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the quarter's performance, particularly in terms of EPS. They emphasized their commitment to pipeline development.
We are pleased with our progress this quarter.
Our focus remains on advancing our pipeline.